Timing
Purchase and sale flow
PurchasesSales
Stock, pipeline and biotech catalyst intelligence
Reported ownership activity
Activity signal
Reported sales exceed purchases by $12.6MOption exercises, awards, and grants are separated from open-market direction.Timing
Composition
Concentration
Company profile
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc. to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
| Insider trading | Relationship | Date | Transaction | Cost | Shares | Value | Shares total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Uihlein Richard E | Director | Jul 31 '26 | Option Exercise | $3.08 | 34,376,167 | $105,806,980 | 44,713,843 | Aug 04 07:52 AM |
| Jamil Khurram | Chief Medical Officer | Jul 14 '26 | Option Exercise | $3.04 | 16,250 | $49,400 | 16,250 | Jul 16 05:39 PM |
| Jamil Khurram | Chief Medical Officer | Jul 14 '26 | Sale | $5.13 | 16,250 | $83,284 | 0 | Jul 16 05:39 PM |
Transactions may include sales, purchases, grants, and option exercises. Directional charts count only purchases and sales; follow the Form 4 link to verify the original SEC filing.